MCID: ACR007
MIFTS: 66

Acromegaly malady

Categories: Rare diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Acromegaly

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 27GTR, 31ICD10 via Orphanet, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Acromegaly:

Name: Acromegaly 11 48 54 12 50 39 13 68
Growth Hormone Excess 48 27
Growth Hormone-Secreting Pituitary Adenoma 68
 
Somatotroph Adenoma 48
Pituitary Giant 48

Characteristics:

Orphanet epidemiological data:

54
acromegaly:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology11 DOID:2449
MeSH39 D000172
NCIt45 C84533
Orphanet54 ORPHA963
MESH via Orphanet40 D000172
UMLS via Orphanet69 C0001206
ICD10 via Orphanet31 E22.0

Summaries for Acromegaly

About this section
NIH Rare Diseases:48 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (gh). it is most often diagnosed in middle-aged adults, although symptoms can appear at any age. signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that; alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. the condition is usually caused by benign tumors on the pituitary called adenomas. rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain stimulating the pituitary gland to produce gh. it is sporadic in 95% of the cases, but almost 50% of the childhood-onset cases have an identifiable gene mutation, most commonly in the aip gene or gpr101 gene. treatment may include hormones, radiotherapy, and surgery. when left untreated, it can result in serious illness and premature death. when gh-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly.   acromegaly may also be part of other genetic syndromes such as multiple endocrine neoplasia syndrome type 1 and type 4, hereditary paraganglioma-pheochromocytoma syndrome, mccune-allright syndrome, neurofibromatosis or carney complex.  last updated: 2/10/2017

MalaCards based summary: Acromegaly, also known as growth hormone excess, is related to ossification of the posterior longitudinal ligament of spine and adrenal adenoma, and has symptoms including Array, Array and Array. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways are Growth hormone receptor signaling and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs octreotide acetate and bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and bone, and related mouse phenotypes are adipose tissue and integument.

Disease Ontology:11 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia:71 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Acromegaly

About this section

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 286)
idRelated DiseaseScoreTop Affiliating Genes
1ossification of the posterior longitudinal ligament of spine31.0GH1, GHR, GHRH, GHRHR, IGF1
2adrenal adenoma29.2GHRL, IGF1, INS, POMC
3pulmonary neuroendocrine tumor28.5AIP, GH1, GHR, MEN1, POMC, PRL
4pituitary adenoma, growth hormone-secreting11.9
5x-linked intellectual disability-acromegaly-hyperactivity syndrome11.8
6pituitary adenoma, growth hormone-secreting 211.5
7gigantism11.2
8pituitary tumors11.1
9mccune-albright syndrome, somatic, mosaic10.8
10pituitary adenoma, prolactin-secreting10.8
11adenoma10.3
12pemphigus vegetans10.3GH1, GHR, SST
13cerebral hemisphere lipoma10.3GH1, PRL, SST
14sohval soffer syndrome10.3IGF1, IGFBP3
15spondylometaphyseal dysplasia, megarbane-dagher-melike type10.3GH1, IGF1, IGFBP3
16seow najjar syndrome10.3IGF1, IGFBP3, INS
17grin2a-related speech disorders and epilepsy10.3GH1, GNAS, PRL
18deafness, autosomal dominant 2510.3GHR, IGF1
19diarrhea 3, secretory sodium, congenital, syndromic10.3IGF1, IGFBP3, INS
20hyperinsulinemic hypoglycemia, familial, 510.3IGF1, IGFBP3, INS
21primary effusion lymphoma10.3GH1, GNAS, IGF1
22burning mouth syndrome type 310.3POMC, SST
23renal hypoplasia, bilateral10.3POMC, SST
24atp7a-related copper transport disorders10.3AIP, GNAS
25water-clear cell adenoma10.2POMC, SST
26epidural spinal canal meningioma10.2IGF1, INS, PRL
27vaginal adenoma10.2IGF1, POMC, SST
28insulin-like growth factor i10.2
29neuritis10.2SST, SSTR2, SSTR5
30pituitary adenoma10.2
31extragonadal nonseminomatous germ cell tumor10.2POMC, PRL, SST
32nonparalytic poliomyelitis10.2POMC, PRL, SST
33bone benign neoplasm10.2IGF1, POMC, PRL
34spondyloepimetaphyseal dysplasia, isidor type10.2AIP, MEN1
35spondylometaphyseal dysplasia, czarny-ratajczak type10.2AIP, MEN1
36gershoni-baruch syndrome10.2PRL, TRH
37paranasal sinus cancer, adult10.2INS, MEN1, SST
38esophagus squamous cell papilloma10.2POMC, PRL, SST
39sphingolipidosis10.2INS, POMC, PRL
40breast secretory carcinoma10.1POMC, SST, SSTR2
41acute pyelonephritis10.1INS, MEN1, SST
42axial osteomalacia10.1GH1, GNAS, IGF1, PRL, SST
43caudal regression syndrome10.1GH1, IGF1, POMC, PRL
44gemistocytic astrocytoma10.1GHRH, MEN1, SST
45necrobiosis lipoidica10.1IGF1, IGFBP3, PRL
46pituitary apoplexy10.1
47brucella canis brucellosis10.1IGF1, IGF2, INS
48dacryoadenitis10.1IGF1, INS, POMC, PRL
49haverhill fever10.1IGF1, IGF2, PRL
50bowen-conradi syndrome10.1AIP, MEN1, PRL

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to acromegaly

Symptoms & Phenotypes for Acromegaly

About this section

Human phenotypes related to Acromegaly:

 54 64 (show all 58)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 long penis64 54 Very frequent (99-80%) HP:0000040
2 abnormality of reproductive system physiology54 Occasional (29-5%)
3 tall stature64 54 Very frequent (99-80%) HP:0000098
4 macroglossia64 54 Very frequent (99-80%) HP:0000158
5 abnormality of the teeth54 Frequent (79-30%)
6 thick lower lip vermilion64 54 Very frequent (99-80%) HP:0000179
7 long face64 54 Very frequent (99-80%) HP:0000276
8 coarse facial features64 54 Very frequent (99-80%) HP:0000280
9 full cheeks64 54 Very frequent (99-80%) HP:0000293
10 mandibular prognathia64 54 Very frequent (99-80%) HP:0000303
11 broad forehead64 54 Very frequent (99-80%) HP:0000337
12 macrotia64 54 Very frequent (99-80%) HP:0000400
13 wide nose64 54 Very frequent (99-80%) HP:0000445
14 synophrys64 54 Frequent (79-30%) HP:0000664
15 widely spaced teeth64 54 Frequent (79-30%) HP:0000687
16 depression64 54 Frequent (79-30%) HP:0000716
17 anxiety64 54 Frequent (79-30%) HP:0000739
18 impotence64 54 Occasional (29-5%) HP:0000802
19 abnormality of the endocrine system54 Very frequent (99-80%)
20 diabetes mellitus64 54 Frequent (79-30%) HP:0000819
21 hypertension64 54 Frequent (79-30%) HP:0000822
22 anterior hypopituitarism64 54 Very frequent (99-80%) HP:0000830
23 acanthosis nigricans64 54 Occasional (29-5%) HP:0000956
24 hyperhidrosis64 54 Very frequent (99-80%) HP:0000975
25 acne64 54 Occasional (29-5%) HP:0001061
26 thickened skin54 Very frequent (99-80%)
27 large hands64 54 Very frequent (99-80%) HP:0001176
28 tapered finger64 54 Very frequent (99-80%) HP:0001182
29 abnormality of the fingernails64 54 Frequent (79-30%) HP:0001231
30 joint swelling64 54 Very frequent (99-80%) HP:0001386
31 hoarse voice64 54 Frequent (79-30%) HP:0001609
32 hypertrophic cardiomyopathy64 54 Occasional (29-5%) HP:0001639
33 mitral regurgitation64 54 Occasional (29-5%) HP:0001653
34 broad foot64 54 Very frequent (99-80%) HP:0001769
35 deep plantar creases64 54 Very frequent (99-80%) HP:0001869
36 frontal bossing64 54 Frequent (79-30%) HP:0002007
37 migraine64 54 Frequent (79-30%) HP:0002076
38 generalized hirsutism64 54 Frequent (79-30%) HP:0002230
39 osteoarthritis64 54 Very frequent (99-80%) HP:0002758
40 arthralgia64 54 Very frequent (99-80%) HP:0002829
41 paresthesia64 54 Frequent (79-30%) HP:0003401
42 spinal canal stenosis64 54 Frequent (79-30%) HP:0003416
43 cortical diaphyseal thickening of the upper limbs64 54 Very frequent (99-80%) HP:0003859
44 macrodactyly64 54 Very frequent (99-80%) HP:0004099
45 deep palmar crease64 54 Very frequent (99-80%) HP:0006191
46 generalized hyperpigmentation64 54 Occasional (29-5%) HP:0007440
47 abnormality of the toenails64 54 Frequent (79-30%) HP:0008388
48 sleep apnea64 54 Frequent (79-30%) HP:0010535
49 fatigue64 54 Very frequent (99-80%) HP:0012378
50 broad jaw64 54 Frequent (79-30%) HP:0012802
51 cerebral palsy64 54 Frequent (79-30%) HP:0100021
52 dysuria64 54 Occasional (29-5%) HP:0100518
53 palpebral edema64 54 Frequent (79-30%) HP:0100540
54 dysmenorrhea64 54 Frequent (79-30%) HP:0100607
55 hypersomnia64 54 Occasional (29-5%) HP:0100786
56 galactorrhea64 54 Occasional (29-5%) HP:0100829
57 kyphosis64 54 Frequent (79-30%) HP:0002808
58 pituitary prolactin cell adenoma64 54 Frequent (79-30%) HP:0006767

MGI Mouse Phenotypes related to Acromegaly according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.2GHR, GHRHR, GHRL, GNAS, IGF1, IGFBP3
2MP:00107717.9AIP, GHR, GHRHR, GNAS, IGF1, IGF2
3MP:00053857.4AIP, GHR, GHRHR, GNAS, GPR101, IGF1
4MP:00053707.4AIP, GHR, GHRH, GNAS, IGF2, IGFBP1
5MP:00053867.0GHR, GHRHR, GHRL, GNAS, IGF2, IGFBP3
6MP:00053876.9GHR, GHRH, GHRHR, GNAS, IGF1, IGF2
7MP:00053786.6AIP, GHR, GHRH, GHRHR, GNAS, IGF1
8MP:00036316.0GHR, GHRH, GHRHR, GNAS, IGF1, IGF2
9MP:00053795.8AIP, GHR, GHRH, GHRHR, GHRL, GNAS
10MP:00053765.2AIP, GHR, GHRH, GHRHR, GHRL, GNAS

Drugs & Therapeutics for Acromegaly

About this section

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 94)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Octreotideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 122383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
2
SomatostatinapprovedPhase 4, Phase 3, Phase 2, Phase 123738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
3
lanreotideapprovedPhase 4, Phase 3, Phase 2, Phase 186108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
4
CabergolineapprovedPhase 4, Phase 34681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
5
DopamineapprovedPhase 4, Phase 3, Phase 2383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
MetforminapprovedPhase 41803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
7
LiraglutideapprovedPhase 4329204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
8
ZincapprovedPhase 422967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
9Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 15592
10AngiopeptinPhase 4, Phase 3, Phase 2, Phase 186
11Insulin, Globin ZincPhase 4, Phase 3, Phase 24645
12insulinPhase 4, Phase 3, Phase 24646
13Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
14Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
15MitogensPhase 4, Phase 3, Phase 21617
16Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
17HormonesPhase 4, Phase 3, Phase 2, Phase 114415
18Complement Factor IPhase 4, Phase 335
19Pharmaceutical SolutionsPhase 48192
20Hypoglycemic AgentsPhase 4, Phase 25896
21Liver ExtractsPhase 44067
22
LactitolPhase 4, Phase 3, Phase 1336585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
23Autonomic AgentsPhase 4, Phase 2, Phase 310150
24Dopamine AgentsPhase 4, Phase 3, Phase 23836
25Antiparkinson AgentsPhase 4, Phase 31574
26Protective AgentsPhase 4, Phase 27443
27Dopamine agonistsPhase 4, Phase 3632
28Neurotransmitter AgentsPhase 4, Phase 3, Phase 218340
29Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 323689
30Sitagliptin PhosphatePhase 4423
31Dipeptidyl-Peptidase IV InhibitorsPhase 4862
32HIV Protease InhibitorsPhase 45470
33
protease inhibitorsPhase 45471
Synonyms:
 
protease inhibitors
34IncretinsPhase 41579
35
Mannitolapproved, investigationalPhase 328069-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
36
Lidocaineapproved, vet_approvedPhase 2, Phase 31317137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
37
Hydrocortisoneapproved, vet_approvedPhase 2, Phase 366750-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
38
Epinephrineapproved, vet_approvedPhase 2, Phase 398551-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
39Carboxymethylcellulose SodiumPhase 3185
40RadiopharmaceuticalsPhase 3514
41EdotreotidePhase 327
42Hydrocortisone 17-butyrate 21-propionatePhase 2, Phase 3667
43Epinephryl boratePhase 2, Phase 3985
44glucocorticoidsPhase 2, Phase 35103
45Respiratory System AgentsPhase 2, Phase 34997
46Vasoconstrictor AgentsPhase 2, Phase 32122
47RacepinephrinePhase 2, Phase 3985
48MydriaticsPhase 2, Phase 3811
49Hydrocortisone acetatePhase 2, Phase 3667
50Bronchodilator AgentsPhase 2, Phase 32965

Interventional clinical trials:

(show top 50)    (show all 147)
idNameStatusNCT IDPhase
1Effects of Sandostatin LAR® in AcromegalyUnknown statusNCT01424241Phase 4
2Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantUnknown statusNCT00552851Phase 4
3Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)Unknown statusNCT00915954Phase 4
4Preoperative Octreotide Treatment of AcromegalyCompletedNCT00521300Phase 4
5Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
6Acute Application of Pegvisomant and Octreotide in AcromegalyCompletedNCT00595140Phase 4
7Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedNCT00627796Phase 4
8Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical TargetCompletedNCT01618513Phase 4
9Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant AcromegalyCompletedNCT00461149Phase 4
10Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4
11A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
12A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520Phase 4
13Octreotide Efficacy and Safety in First-line Acromegalic PatientsCompletedNCT00171886Phase 4
14Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic PatientsCompletedNCT01014793Phase 4
15Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionCompletedNCT00145405Phase 4
16Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
17A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.CompletedNCT01861717Phase 4
18Canadian Pegvisomant Compassionate Study In Acromegalic PatientsCompletedNCT00151437Phase 4
19Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
20Non Interventional Study For Patients Treated With Somavert®CompletedNCT00858143Phase 4
21Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4
22Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
23Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4
24Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227Phase 4
25Surgical Debulking of Pituitary AdenomasCompletedNCT01371643Phase 4
26Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From AcromegalyRecruitingNCT02115906Phase 4
27Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
28Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin AnaloguesRecruitingNCT02427295Phase 4
29Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
30Pasireotide LAR and Pegvisomant Study in AcromegalyActive, not recruitingNCT02668172Phase 4
31Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
32Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
33Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3
34Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyCompletedNCT01137682Phase 3
35Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3
36Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyCompletedNCT02493517Phase 3
37Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
38Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedNCT00600886Phase 3
39Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
40Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3
41Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
42Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
43Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2, Phase 3
44Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00635765Phase 3
45Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00616551Phase 3
46Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3
47A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
48Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3
49Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
50Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyRecruitingNCT02685709Phase 3

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

About this section

Genetic tests related to Acromegaly:

id Genetic test Affiliating Genes
1 Growth Hormone Excess27

Anatomical Context for Acromegaly

About this section

MalaCards organs/tissues related to Acromegaly:

36
Pituitary, Bone, Skin, Testes, Brain, Pancreas, Lung

FMA organs/tissues related to Acromegaly:

17
Limb

Publications for Acromegaly

About this section

Articles related to Acromegaly:

(show top 50)    (show all 1497)
idTitleAuthorsYear
1
Persistent reduction of circulating myeloid calcifying cells in acromegaly. Relevance to the bone-vascular axis. (28323966)
2017
2
Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly. (28469926)
2017
3
Suffocation due to Thoracic Deformity Caused by Acromegaly. (28420845)
2017
4
Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. (28042644)
2017
5
Assessment of Nasal Carriage of Staphylococcus Aureus and Axillar Flora in Patients With Acromegaly. (28060097)
2017
6
Treatment of acromegaly patients at the Federal University of TriAcngulo Mineiro (UFTM): Experience Report. (28492721)
2017
7
Bone Material Strength index as measured by impact microindentation is altered in patients with acromegaly. (28077497)
2017
8
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. (27896545)
2017
9
HIGH-DOSE AND HIGH-FREQUENCY LANREOTIDE AUTOGEL IN ACROMEGALY: A RANDOMIZED, MULTICENTER STUDY. (28419317)
2017
10
An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly. (28469929)
2017
11
Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly. (28465267)
2017
12
Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. (28368500)
2017
13
GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment. (28490347)
2017
14
Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1A levels following pituitary surgery in acromegaly. (28341329)
2017
15
The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens. (28402548)
2017
16
Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: a case report. (28390105)
2017
17
Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. (28372573)
2017
18
Assessment of lung function in a large cohort of patients with acromegaly. (28432267)
2017
19
Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients. (28332074)
2017
20
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. (27932528)
2017
21
Calcium and bone turnover markers in acromegaly: a prospective controlled study. (28407138)
2017
22
Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients. (28508245)
2017
23
Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients. (28357781)
2017
24
Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. (27910111)
2017
25
Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. (28477735)
2017
26
Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. (27932529)
2017
27
Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. (27913611)
2017
28
Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. (27153851)
2016
29
General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers. (27033692)
2016
30
Combination of Klinefelter Syndrome and Acromegaly: A Rare Case Report. (27124035)
2016
31
Ectopic Acromegaly Arising from a Pituitary Adenoma within the Bony Intersphenoid Septum of a Patient with Empty Sella Syndrome. (27468406)
2016
32
Role of ambulatory blood pressure monitoring in patients with acromegaly. (27153464)
2016
33
Leptin Receptor Gene Polymorphism may Affect Subclinical Atherosclerosis in Patients with Acromegaly. (27563428)
2016
34
Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naA^ve active acromegaly. (27117887)
2016
35
Childhood acromegaly due to X-linked acrogigantism: long term follow-up. (27631333)
2016
36
Patients cured of acromegaly do not experience improvement of their skull deformities. (27590786)
2016
37
Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study. (28012070)
2016
38
Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naA^ve acromegaly patients: a prospective study at baseline and after 1A year of somatostatin analogs treatment. (27591859)
2016
39
Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. (27631335)
2016
40
Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. (28042650)
2016
41
Patients with Acromegaly Presenting with Colon Cancer: A Case Series. (28025627)
2016
42
Acromegaly in sleep apnoea patients: a large observational study of 755 patients. (27660510)
2016
43
Coexistence of acromegaly with dural arteriovenous fistula of the cavernous sinus. (27194169)
2016
44
Genetics of gigantism and acromegaly. (27657986)
2016
45
Pregnancy and acromegaly. (27568329)
2016
46
Pasireotide (SIGNIFOR) in acromegaly. After treatment failure: better than pegvisomant. (27042726)
2016
47
Auditory changes in acromegaly. (28035526)
2016
48
Pituitary apoplexy causing spontaneous remission of acromegaly following long-acting octreotide therapy: a rare drug side effect or just a coincidence. (27123308)
2016
49
Three-dimensional soft tissue analysis of the hand: a novel method to investigate effects of acromegaly. (27932856)
2016
50
MANAGEMENT OF ENDOCRINE DISEASE: ACROMEGALY AND CANCER: AN OLD DEBATE REVISITED. (27089890)
2016

Variations for Acromegaly

About this section

Expression for genes affiliated with Acromegaly

About this section
Search GEO for disease gene expression data for Acromegaly.

Pathways for genes affiliated with Acromegaly

About this section

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8GH1, GHR, PRL
29.7IGF1, IGFBP3, INS
39.6GNAS, IGF1, INS
49.4IGF1, IGF2, INS
59.3GH1, GHR, IGF1, INS, PRL
69.2GH1, GHR, IGF1, IGF2
7
Show member pathways
8.9IGF1, IGF2, IGFBP1, IGFBP3
88.9IGF1, IGF2, IGFBP1, IGFBP3
98.9GHRH, GHRHR, GNAS, POMC
108.8GH1, GHRH, GNAS, IGF1, IGF2
11
Show member pathways
8.6GHRL, GNAS, SSTR2, SSTR5
12
Show member pathways
8.5GH1, GHRL, IGF1, INS, POMC
13
Show member pathways
8.5GH1, GHRH, GNAS, IGF1, IGF2, INS
14
Show member pathways
8.0GH1, GHR, GHRH, GNAS, IGF1, IGF2
15
Show member pathways
6.3GH1, GHR, GHRH, GHRHR, GHRL, GNAS
16
Show member pathways
5.3GHRH, GHRHR, GHRL, GNAS, IGF1, IGF2

GO Terms for genes affiliated with Acromegaly

About this section

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1growth hormone receptor complexGO:007019510.6GH1, GHR
2insulin-like growth factor binding protein complexGO:001694210.5IGF1, IGFBP3
3insulin-like growth factor ternary complexGO:004256710.5IGF1, IGFBP3
4endosome lumenGO:003190410.5GH1, INS, PRL
5secretory granuleGO:00301419.0GHRHR, POMC, PRL, TRH
6endoplasmic reticulum lumenGO:00057888.9GHRL, IGFBP1, IGFBP3, INS, MEN1
7extracellular spaceGO:00056157.0GH1, GHR, GHRH, GHRL, IGF1, IGF2
8extracellular regionGO:00055766.3GH1, GHR, GHRH, GHRL, GNAS, IGF1

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 36)
idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor receptor signaling pathwayGO:004800910.8GHR, IGF1
2growth hormone receptor signaling pathwayGO:006039610.8GH1, GHR
3positive regulation of glycolytic processGO:004582110.7IGF1, INS
4negative regulation of feeding behaviorGO:200025210.7INS, TRH
5positive regulation of tyrosine phosphorylation of STAT proteinGO:004253110.6GH1, GHR, IGF1
6positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.6GH1, GHR, IGF1
7JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.6GH1, GHR, PRL
8positive regulation of JAK-STAT cascadeGO:004642710.5GH1, GHR, PRL
9regulation of multicellular organism growthGO:004001410.5GHR, IGF1, PRL
10positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.5GH1, IGF1, INS
11adenohypophysis developmentGO:002198410.5GHRH, GHRHR
12positive regulation of hormone secretionGO:004688710.5GHRH, GHRHR
13response to nutrientGO:000758410.4PRL, SST, SSTR2
14positive regulation of insulin receptor signaling pathwayGO:004662810.3IGF2, INS
15adenylate cyclase-activating G-protein coupled receptor signaling pathwayGO:000718910.1GHRH, GHRHR, GNAS
16positive regulation of glycogen biosynthetic processGO:004572510.1IGF1, IGF2, INS
17positive regulation of mitotic nuclear divisionGO:004584010.1IGF1, IGF2, INS
18positive regulation of cAMP biosynthetic processGO:003081910.1GHRH, GHRHR, GNAS
19regulation of insulin-like growth factor receptor signaling pathwayGO:004356710.0GHRHR, IGFBP1, IGFBP3
20hormone-mediated signaling pathwayGO:00097559.9GHR, GHRL, TRH
21positive regulation of circadian sleep/wake cycle, non-REM sleepGO:00460109.9GHRHR, GHRL
22insulin receptor signaling pathwayGO:00082869.9IGF2, IGFBP1, INS
23positive regulation of MAPK cascadeGO:00434109.8IGF1, IGF2, IGFBP3, INS
24somatostatin signaling pathwayGO:00381709.8SSTR2, SSTR5
25positive regulation of insulin-like growth factor receptor signaling pathwayGO:00435689.8GH1, GHRH, GHRHR, IGF1, IGFBP3
26positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.7GH1, GHR, IGF1, IGF2, INS
27growth hormone secretionGO:00302529.7GHRH, GHRHR, GHRL
28positive regulation of growth hormone secretionGO:00601249.6GHRH, GHRHR, GHRL
29negative regulation of cell proliferationGO:00082859.6IGFBP3, MEN1, SST, SSTR2, SSTR5
30glucose metabolic processGO:00060069.5GHRL, IGF2, INS
31cell-cell signalingGO:00072679.3GHRH, GPR101, INS, POMC, SST, SSTR2
32positive regulation of multicellular organism growthGO:00400189.2GH1, GHR, GHRH, GHRHR, GHRL
33positive regulation of cell proliferationGO:00082849.1GHRH, GHRHR, IGF1, IGF2, INS, PRL
34cellular protein metabolic processGO:00442678.7IGF1, IGF2, IGFBP1, IGFBP3, INS, MEN1
35G-protein coupled receptor signaling pathwayGO:00071868.2GHRHR, GHRL, GNAS, GPR101, INS, SST
36signal transductionGO:00071657.3AIP, GHRHR, GNAS, GPR101, IGF1, IGFBP1

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor I bindingGO:003199410.2IGFBP1, IGFBP3
2prolactin receptor bindingGO:000514810.1GH1, PRL
3insulin-like growth factor II bindingGO:003199510.1IGFBP1, IGFBP3
4growth hormone-releasing hormone activityGO:001660810.0GHRH, GHRL
5somatostatin receptor activityGO:00049949.8SSTR2, SSTR5
6growth factor bindingGO:00198389.8GHRHR, IGFBP1, IGFBP3
7insulin receptor bindingGO:00051589.8IGF1, IGF2, INS
8insulin-like growth factor receptor bindingGO:00051599.2GNAS, IGF1, IGF2, INS
9hormone activityGO:00051797.7GH1, GHRL, IGF1, IGF2, INS, POMC

Sources for Acromegaly

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet